Relationship Proteases - Transglutaminases

Transglutaminases catalyze the acyl-transfer reaction between a γ-carboxamide group of glutamine and the ε-amino group of lysine, which results in the formation of isopeptide bonds. Human transglutaminases possess a catalytic triad and the reaction proceeds via a reactive intermediate linked to the nucleophilic cysteine of the enzyme. The mechanism is similar to the proteolysis reaction catalyzed by thiol proteases that posses the same catalytic triad. It turned out that transglutaminases are using a similar structural architecture as papain-like thiol proteases and obviously even have an evolutionary relationship.

Also biology and physiology are closely related. E.g. the transglutaminase coagulation factor XIIIa cross-links fibrin and therefore plays an important role in blood clot formation. The serine protease thrombin (T056) activates factor XIII cleaving the activation peptide. Subsequently, plasmin (P012) degrades the fibrin clot. Therefore proteases are important tools in transglutaminase research.

Art. No.
D005 Metalloprotease-Assay-Substance
2 mg
310 €
P003 Prolylendopeptidase from Myxococcus xanthus, recombinant
150 U
370 €
P009 human Pro-Glu-Plasminogen, recombinant
100 µg
415 €
P012 human Plasmin, recombinant
(from Glu-Plasminogen, activated by Urokinase)
100 µg
415 €
P014 Urokinase
1 mg
370 €
P016 Tissue Plasminogen Activator, t-PA
100 µg
370 €
T004 Plasmin substrate Tosyl-GPKpNA, chromogenic
N-(p-Tosyl)-Gly-Pro-Lys-pNA acetate
25 mg
315 €
T056 Human alpha thrombin, highly active
200 U
185 €
T090 Thrombin, recombinant
20 µg
370 €
T091 Prothrombin, recombinant
20 µg
370 €


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation




    13.11.2017 - 16.11.2017
    Düsseldorf, Germany

  • Gordon Research Conference on: Transglutaminases in Human Disease Processes

    16.06.2018 - 17.06.2018
    Les Diablerets, Switzerland